Delving into the Latest Updates on R-Pharm JSC with Synapse

Overview

Tags

Respiratory Diseases

Infectious Diseases

Skin and Musculoskeletal Diseases

Small molecule drug

Fusion protein

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	3
Neoplasms	2
Immune System Diseases	2
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Small molecule drug	5
Fusion protein	2
Monoclonal antibody	1

Top 5 Target	Count

IL-6(Interleukin-6)	1
TGF-β(Transforming growth factor beta)	1
IL-1β(Interleukin-1 beta)	1
M1 receptor x M3 receptor	1
Opioid receptors	1

The goal of this retrospective registry is to evaluate the efficacy and safety of Refralon®, concentrate for solution for intravenous injection, as chemical cardioversion in patients with paroxysmal and persistent atrial fibrillation and flutter in routine clinical practice. The main questions it aims to answer are:
What is the incidence of sinus rhythm restoration within 6 hours in patients with paroxysmal atrial fibrillation (AF)/atrial flutter (AFL) after the first dose of Refralon®?
What is the incidence of sinus rhythm restoration within 24 hours in patients with persistent AF/AFL after the first dose of Refralon®?

Start Date11 Nov 2022

Sponsor / Collaborator

R-Pharm JSC

100 Clinical Results associated with R-Pharm JSC

Login to view more data

0 Patents (Medical) associated with R-Pharm JSC

Login to view more data

13

Literatures (Medical) associated with R-Pharm JSC

13 Aug 2024·Circulation

Results of International, Double-Blind, Randomized, Placebo-Controlled, Phase IIa Study of Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment–Elevation Myocardial Infarction (STEMI)

Letter

Author: Meray, Imad ; Staroverov, Ilya ; Bogin, Vlad ; Rozanov, Denis ; Cremer, Paul C. ; Selezneva, Natalia ; Ponomar, Ekaterina G. ; Mekhriakov, Sergei ; Lonchakova, Oxana ; Pereverzeva, Kristina ; Safarian, Vakhtang ; Popov, Nikolay ; Abbate, Antonio ; Agirov, Murat ; Savelieva, Ekaterina ; Golino, Michele ; Duhanina, Ekaterina ; Buono, Marco Giuseppe Del ; Babaeva, Lala ; Kotova, Anastasia ; Markley, Roshanak ; Fedash, Andrey ; Privalova, Olga ; Mayorov, Vyacheslav ; Zyuryaev, Ilya ; Yakushin, Sergey ; Kalimulin, Denis ; Ivanova, Galina ; Zubova, Ekaterina ; Talasaz, Azita H. ; Marawan, Amr ; Taylor, Angela ; Lavrovsky, Yan ; Pevzner, Dmitry V. ; Grishin, Sergey A. ; Samsonov, Mikhail Yu ; Novosadov, Vladimir ; Osmanova, Samra ; Nilk, Rostislav ; Pisaryuk, Alexandra ; Lapin, Oleg ; Shogenov, Zaur ; Van Tassell, Benjamin ; Kalashnikov, Igor ; Yurkovskiy, Andrey ; Damonte, Juan Ignacio ; Thomas, Georgia ; Turlington, Jeremy S. ; Egorova, Alina N. ; Kornilov, Egor ; Privalov, Dmitry V. ; Pravkina, Ekaterina ; Seleznev, Sergey

01 Jul 2023·Journal of the American College of Cardiology

Treatment of Idiopathic Recurrent Pericarditis With Goflikicept

Article

Author: Maslyanskiy, Alexey L ; Lavrovsky, Yan ; Grishin, Sergey A ; Schedrova, Margarita L ; Gleykina, Ekaterina V ; Egorova, Alina N ; Samsonov, Mikhail Yu ; Abbate, Antonio ; Myachikova, Valentina Yu ; Moiseeva, Olga M ; Vinogradova, Oksana V

BACKGROUNDIdiopathic recurrent pericarditis (IRP) is a rare autoinflammatory disease. Interleukin (IL)-1α and IL-1β are the pivotal cytokines in the pathophysiology of acute pericarditis and its recurrence. We created a phase II/III study with a new IL-1 inhibitor-goflikicept in IRP.OBJECTIVESThis study sought to evaluate the efficacy and safety of goflikicept treatment in patients with IRP.METHODSWe conducted a 2-center open-label study of goflikicept in patients with IRP with and without recurrence at time of enrollment. The study consisted of 4 periods: screening, run-in (open-label treatment period), randomized withdrawal, and follow-up. Patients with clinical response to goflikicept in the run-in period were randomized (1:1) to a placebo-controlled withdrawal period, where the time to first pericarditis recurrence (primary endpoint) was evaluated.RESULTSWe enrolled 22 patients, and 20 of these patients were randomized. Reduction of C-reactive protein level accompanied by reduction of chest pain and pericardial effusion compared to baseline was demonstrated during the run-in period. Recurrence of pericarditis occurred in 9 of 10 patients in the placebo group, and there were no recurrence events in goflikicept group within 24 weeks after randomization (P < 0.001). A total of 122 adverse events were reported in 21 patients (95.5%), with no deaths and no new safety signals identified for goflikicept.CONCLUSIONSTreatment with goflikicept prevented recurrences and maintained IRP remission with a favorable risk-benefit ratio. Goflikicept reduced the risk of recurrence compared with placebo. (Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis; NCT04692766).

01 Jan 2020·Terapevt (General Physician)

Pharmacological means of personalized medicine: main global trends.

Author: Lomonosov, A. ; Samsonov, M.

The article analyzes international trends and prerequisites for the formation of a fundamentally new direction in the global and national health systems in the coming years – personalized pharmacology. This will affect all participants of the pharmaceutical market and will actually change its appearance beyond recognitionfrom scenarios for the development, production and testing of drugs to the approval of algorithms for their application, training of specialists in personalized clinical pharmacology and the system of financing the prevention and treatment of socially significant diseases.

100 Deals associated with R-Pharm JSC

Login to view more data

100 Translational Medicine associated with R-Pharm JSC

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

2

Preclinical

Phase 3 Clinical

1

4

NDA/BLA

Other

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Imidafenacin ( M1 receptor x M3 receptor )	Pollakisuria More	NDA/BLA
Olokizumab ( IL-6 )	Rheumatoid Arthritis More	NDA/BLA
Nemonoxacin Malate ( Bacterial DNA gyrase x Topoisomerase IV )	Infectious Diseases More	NDA/BLA
Odelepran ( Opioid receptors )	Alcoholism More	NDA/BLA
Goflikicept ( IL-1β )	Idiopathic Recurrent Pericarditis More	Phase 3